IP Library Granted Patent US 9,778,267
Granted Patent B2
US 9,778,267 · App. 12/171,475 · Granted Oct 3, 2017

Methods for identifying modulators of ion channels

Inventors: Brant Binder (Chestnut Hill, MA); Lance Laing (Belmont, MA)
Assignee: X-Body, Inc.
G01N33/6872G01N33/54373
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,778,267
App. No.
12/171,475
Granted
Oct 3, 2017
Kind
B2
Abstract

The invention provides methods for identifying modulators of ion channels without the use of recombinant cell lines over-expressing the ion channel proteins or the use of detection labels.

Claims (27)

1. A method of identifying a compound that is a modulator of an ion channel comprising:

(a) applying cells to a first location and a second location on a surface of colorimetric resonant reflectance optical biosensor;

(b) applying a test reagent compound to the first location;

(c) applying a compound that is a known ion channel modulator of the cells to the second location;

(d) detecting a colorimetric resonant reflectance optical first peak wavelength value (PWV) for the first location and detecting a second PWV for the second location; wherein if the first and second PWVs are the same or similar, then the test reagent compound is a modulator of an ion channel; and wherein if the first and second PWVs are substantially different, then the test reagent is not a compound that is a modulator of an ion channel.

2. The method of claim 1 , wherein the cells are incubated for a period of time after their application to the first location; after the application of the test reagent compound to the first location; after the cells are applied to the second location, after the known ion channel modulator is applied to the second location, or a combination thereof.

3. The method of claim 1 , wherein the PWV is detected using a scanner with a lens having a lower limit pixel size of about 2 micrometers to about 200 micrometers.

4. The method of claim 1 , wherein the first location and second location on the surface of the colorimetric resonant reflectance optical biosensor is an internal surface of a vessel selected from the group consisting of a microtiter well, microtiter plate, test tube, Petri dish, microfluidic channel, and microarray.

5. The method of claim 1 , wherein the cells, test reagent, and ion channel modulator do not comprise detection labels.

6. The method of claim 1 , wherein the method is performed at a temperature of about 25, 30, or 37 degrees Celsius.

7. The method of claim 1 , wherein the cells are non-recombinant cells.

8. The method of claim 1 wherein the cells are immobilized to the first location and second location via a functional linker.

9. The method of claim 8 , wherein the functional linker is a nickel group, an amine group, an aldehyde group, an acid group, an alkane group, an alkene group, an alkyne group, an aromatic group, an alcohol group, an ether group, a ketone group, an ester group, an amide group, an amino acid group, a nitro group, a nitrile group, a carbohydrate group, a thiol group, an organic phosphate group, a lipid group, a phospholipid group or a steroid group.

10. The method of claim 1 , wherein the cells are immobilized to the first location and the second location by chemical binding or electrochemical binding.

11. The method of claim 1 , wherein the surface of colorimetric resonant reflectance optical biosensor is coated with poly-D-lysine, fibronectin, actin, integrins, adherins, cadherins, collagen, or laminin.

12. The method of claim 1 , wherein a pattern of PWV values are recorded over time for the first location and the second location.

13. The method of claim 1 , wherein the known ion channel modulator is nisoldipine, nifedipine, nicardipine, bepridil, isradipine, nimodipine, felodipine, amlodipine, diltiazem, or verapamil.

14. The method of claim 1 , wherein the test reagent compound is lidocaine, novocaine, dedrotoxin, conotoxin, saxitoxin, or tetrodotoxin.

15. The method of claim 1 , wherein the cells are mammalian cells.

16. The method of claim 1 , wherein the cells are adherent cells.

17. The method of claim 1 , wherein the modulator of an ion channel is an ion channel antagonist or an ion channel agonist.

18. The method of claim 1 , wherein the known modulator of an ion channel is an ion channel antagonist or an ion channel agonist.

19. The method of claim 1 , wherein the compound that is a modulator of an ion channel blocks, inhibits, enhances or increases the activity of an ion channel.

20. A method of identifying a compound that is a modulator of an ion channel comprising:

(a) applying cells to a surface of colorimetric resonant reflectance optical biosensor;

(b) applying a test reagent compound to the cells;

(c) detecting a first colorimetric resonant reflectance optical peak wavelength value (PWV) pattern for the cells over time and comparing the first PWV pattern for the cells over time to a second PWV pattern for cells treated with a known ion channel modulator over time, wherein if the first and second PWV patterns are the same or similar, then the test reagent compound is a modulator of an ion channel.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2012
From: SRU BIOSYSTEMS, INC.
To: X-BODY, INC.
Reel/Frame 028014/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2008
From: BINDER, BRANT; LAING, LANCE
To: SRU BIOSYSTEMS INC
Reel/Frame 021606/0017 →
Continuity (2)
Provisional Application 60949142 · Jul 11, 2007
Related Publication 20090017488A1 · Jan 15, 2009